| Document |
Document Title |
|
JP5210971B2 |
The present invention relates to a compound having formula: wherein (a) either A or B is a double bond such that when A is a double bond, C 11 has substituted thereon =X, and when B is a double bond, C 12 has substituted thereon =X, X be...
|
|
JP5203950B2 |
Disclosed are large-scale industrial processes for obtaining highly pure betulinic acid from ground plane bark. Betulinic acid is 3beta-hydroxy-lup-20(29)-ene-28-oic acid of formula
|
|
JP2013519674A |
The present invention relates to a compound characterized by the following Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, X, and Y are as described herein. Compounds of the present invention are useful for ...
|
|
JPWO2011074607A1 |
Provided are a triterpene derivative represented by the general formula (I) or a pharmaceutically acceptable salt thereof, and an agent containing the triterpene derivative as an active ingredient for the prevention or treatment of chron...
|
|
JP2013053108A |
To provide a skin external medication containing camellia flowers or extracts thereof, to provide novel Camelliosides including a Camellioside formulae (1), (4) isolated from the extracts and further to provide a manufacturing method for...
|
|
JP5134530B2 |
New salts or ion-pair complexes obtained by a reaction between boswellic acids or selectively enriched 3-O-acetyl-11-keto-beta-boswellic acid (AKBA) or 11-keto-beta-boswellic acid (KBA) compounds obtained through a new improved process, ...
|
|
JP2012532831A |
There is provided a medicament capable of enhancing the antimicrobial peptide production ability. The medicament contains, as an active ingredient, a compound which is glycyrrhizin or a pharmaceutically acceptable salt thereof and capabl...
|
|
JP5087400B2 |
Novel compounds such as compounds designated herein as Xanifolia-Y or -Y3, -Y1, -Y2, -Y8, -Y9 and -Y10 are disclosed. These compounds have anticancer activity. The compounds of the present invention are obtainable from plants in the sapi...
|
|
JP5080249B2 |
In a triterpenic acid having hydroxyl groups, at least one of the hydroxyl groups is phosphorylated to produce a phosphorylated triterpenic acid and/or a salt thereof, thereby improving the solubility of the triterpenic acid in a prepara...
|
|
JP2012188438A |
To provide novel forms of CDDO methyl ester.A triterpenoid compound, methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate (CDDO methyl ester), has a non-crystalline, glassy solid form and a non-hydrous crystalline form that can be prepare...
|
|
JP5005812B2 |
A triterpenoid compound, methyl 2-cyano-3,12-dioxo-Ieana- 1,9(11)-dien-28-oate (CDDO methyl ester), has a crystalline, glassy solid form and a non-hydrous crystalline form that can prepared, for example, from a saturated methanol solutio...
|
|
JP2012144574A |
To provide compounds and methods useful for chemopreventative treatment of diseases such as cancer, Alzheimer's disease, Parkinson's disease, inflammatory bowel diseases, and multiple sclerosis.Triterpenoid derivatives, such as 2-cyano-3...
|
|
JP4958452B2 |
|
|
JP4923146B2 |
The present invention concerns methods for treating and preventing renal/kidney disease, insulin resistance/diabetes, fatty liver disease, and/or endothelial dysfunction/cardiovascular disease using synthetic triterpenoids, optionally in...
|
|
JP4903309B2 |
This invention relates to new Gymnemic acid derivatives, their preparation, pharmaceutical composition or extract which contains them, and their medical use, especially the use in the prevention or treatment of the diseases associated wi...
|
|
JP2012056917A |
To provide an antimicrobial agent composition having superior antimicrobial effect and high safety to human body.The antimicrobial agent composition includes glycyrrhetinic acid or its derivative and an aluminum salt. There is further di...
|
|
JP2012056937A |
To provide improvement and/or care of skin quality by inhibiting activation and/or expression of matrix metalloproteinase (MMP), inhibiting the phosphorylation of mitogen-activated protein kinase (MAPK), and/or promoting expression of co...
|
|
JPWO2010044371A1 |
Sweet receptor agonists such as Acesulfarm K, sucralose, saccharin or glycyrrhizin are used as active ingredients of insulin secretagogues. In addition, a test compound is added to cells expressing a sweet taste receptor, the sweet taste...
|
|
JP4895552B2 |
|
|
JP2012041294A |
To provide a drug, food or the like capable of repairing spinal cord injury, which has simple and high effects.The spinal cord injury repair promoter contains soybean saponin as an active ingredient.
|
|
JP4880479B2 |
This invention provides methods and process of identification and producing pure, biologically active compound(s) from Xanthoceras sorbifolia. This invention also provides the composition of the pure compound(s) of interest from Xanthoce...
|
|
JP2012025719A |
To provide a proton pump inhibiting agent which allows routine ingestion over a long period of time without safety concerns.The proton pump inhibiting agent includes ursolic acid as active ingredient.
|
|
JP4871274B2 |
The invention relates to novel 2-substituted D-homo-estra-1,3,5(10)-trienes of general formula (I) wherein R2 represents a C1-C8 alkyl, a C1-C8 alkyloxy group or a halogen atom, R13 represents a hydrogen atom or a methyl group, and R17 r...
|
|
JP4854939B2 |
To provide a melanogenesis inhibitor having high melanogenesis inhibitory or bleaching effect and substantially free of discoloration and toxicity to mammals, especially humans, through solving problems in view of the fact that although ...
|
|
JP4827189B2 |
Process of oxidizing an alcohol in an amide solvent with use of a mixed reagent containing hydrogen peroxide and a tungsten catalyst.
|
|
JP4828135B2 |
To provide a highly safe inhibitor for taking cholesterol into lipid micelles especially useful for preventing and treating hyperlipidemia. The inhibitor comprises a compound expressed by formula (1), wherein R1expresses a cinnamic acid ...
|
|
JP4810642B2 |
|
|
JP4813917B2 |
|
|
JP4790620B2 |
Various compounds obtained from plants of the Barringtonia species which are derived from Barringtoside A and Barringtoside C as precursor compounds which especially have an arabinopyranosyl substituent at the 21 position which may optio...
|
|
JP4781624B2 |
The object of the present invention is to provide the use of glycyrrhizin and its derivatives for induction of RANTES. The present invention discloses an RANTES induction method and pharmaceutical composition for the same comprising admi...
|
|
JP4769868B2 |
The present invention relates to a method of producing corosolic acid by using plant cells that produce corosolic acid. More particularly, the present invention relates to a method of producing corosolic acid by using plant cell suspensi...
|
|
JP4753581B2 |
The present invention includes the use of pelorol, related compounds and pharmaceutical compositions thereof as modulators of SHIP 1 activity. This invention also provides novel terpene compounds capable of modulating SHIP I activity and...
|
|
JP2011522038A |
The present invention relates to the use of triterpenoid-based compounds of formula (1) for inhibiting viral activity. The triterpenoid-based compounds have an excellent effect of inhibiting viral activity, and thus will be useful as the...
|
|
JP4732454B2 |
This invention relates to novel corosolic acid analogs of the formula I, wherein R1, R2, R3, R4 and R5 are described herein. These compounds exhibit good hypoglycemic and 5-lipoxygenase inhibitory activities. They also inhibit tumour gro...
|
|
JP4722031B2 |
The present invention relates to novel betulinic acid derivatives with increased activity for the treatment of carcinomas and HIV diseases, a method for preparing such novel betulinic acid derivatives as well as their use as pharmaceutic...
|
|
JP4718439B2 |
This invention relates to 2-substituted D-homo-estra-1,3,5(10)-trien-3-yl sulfamates of general formula I (I), in which R3 means a C1-C5-alkyl or C1-C5-alkyloxy group as well as their use for the production of a pharmaceutical agent for ...
|
|
JP4707115B2 |
Disclosed herein are a novel crystal of a novel triterpene derivative, a method for producing the crystals, and a pharmaceutical preparation obtained by using the crystals. The novel crystal is a crystal of a compound (I) of the formula ...
|
|
JP2011516457T |
For medical treatment of a process of a disease relevant to activation of COX*2 in the present invention, It is related with symptomatic medical treatment and/or regenerative medical treatment of arthropathy, rheumatoid arthritis, fibrom...
|
|
JP2011516457A |
The invention relates to the use of maslinic acid or natural, synthetic or semi-synthetic maslinic-rich mixtures or of a composition containing said acid for the treatment of pathological processes associated with COX-2 activation, inten...
|
|
JP4675903B2 |
The present invention relates to the triterpene compounds improving in brain functions. In particular, the present invention relates to a novel use of the triterpene compounds represented by the Formula 1 for improving decreased memory a...
|
|
JP2011511812A |
The invention relates to 17β lupane derivatives of formula (I): wherein R1 and X are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, the inventi...
|
|
JP4664433B2 |
New aminoalkoxyimino derivatives at position 3 of substituted B-homoandrostanes and B-heteroandrostanes, processes for their preparation, and to pharmaceutical compositions containing them for the treatment of cardiovascular disorders, s...
|
|
JP2011508748A |
The invention relates to 21-keto triterpene compounds of formula (I): wherein R1, X, and Y are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, th...
|
|
JP2011508747A |
The invention relates to 21 -keto triterpene compounds of formula (I): wherein R1, X and Y are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, th...
|
|
JP4649549B2 |
Disclosed is a gap junction inhibitor which is more practically useful compared with carbenoxolone. Also disclosed is a novel glycyrrhetinic acid derivative. The glycyrrhetinic acid derivative is represented by general formula (1) or (2).
|
|
JP4642330B2 |
This invention relates to a use of hederagenin 3-O- alpha -L-rhamnopyranosyl((1->2)-Ä beta -D-glucopyranosyl(1->4)Ü- alpha -L-arabinopyranoside or a Pulsatillae radix extract containing the same as a therapeutic agent for solid tumors.
|
|
JP4643275B2 |
Production of an extract (A) of Centella asiatica, containing a mixture of madecassoside (I) and terminoloside (II), involves: (a) extracting above-ground plant parts with alcoholic solvent; (b) passing the extract through anionic resin;...
|
|
JP4632024B2 |
To provide a method for producing soybean saponin, capable of easily purifying and obtaining the high-purity saponin, especially a soybean saponin B group having high biological activity. This method for producing the high-purity soybean...
|
|
JP4623946B2 |
|
|
JP2011012065A |
To provide a method improved for treating disease states in which pathogenic cell populations such as cancer cells are present.The improved method is to enhance specific elimination of pathogenic cell populations mediating endogenous imm...
|
